Literature DB >> 14680976

Mild citrullinemia in Caucasians is an allelic variant of argininosuccinate synthetase deficiency (citrullinemia type 1).

Johannes Häberle1, Silke Pauli, Eva Schmidt, Barbara Schulze-Eilfing, Christoph Berning, Hans Georg Koch.   

Abstract

Citrullinemia is caused by either deficiency of argininosuccinate synthetase (ASS, citrullinemia type 1) or a defect of the SLC25A13 gene encoding a mitochondrial aspartate-glutamate transporter (citrullinemia type II). Citrullinemia type 1-referred to as classical citrullinemia-is characterized by largely elevated concentrations of citrulline, manifesting with acute hyperammonemic crises predominantly early in life and occurs panethnically. Citrullinemia type II is a rare multisystem-disorder nearly exclusively observed in the Japanese population and characterized by less pronounced elevations of plasma citrulline and mainly a late onset of clinical symptoms. Here, we investigated 21 citrullinemic patients (mean peak plasma citrulline 1023 micromol/l, range 152-3360), all of whom remained asymptomatic during the observation period (6-156 months). These patients were referred to as mild citrullinemia due to less striking peak citrulline concentrations or absent clinical symptoms. Extended newborn screening using tandem mass spectrometry detected 15/21 patients, 4/21 patients were identified by investigation of siblings, 2/21 during metabolic work-up of unspecific neurological symptoms. We characterized the genetic defects in all affected families and found all patients affected by citrullinemia type 1 due to mutations of the ASS gene. We identified 15 different mutations, 14/15 missense and 1/15 nonsense, 6/15 were novel mutations. This is the first genetic study in a series of patients with hitherto asymptomatic citrullinemia. According to the mutations found in this study, mild citrullinemia seems to be primarily related to the human ASS gene, at least in patients of caucasian origin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14680976     DOI: 10.1016/j.ymgme.2003.08.002

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  16 in total

1.  Expanded newborn screening: reducing harm, assessing benefit.

Authors:  Bridget Wilcken
Journal:  J Inherit Metab Dis       Date:  2010-05-04       Impact factor: 4.982

2.  Newborn screening.

Authors:  James J Pitt
Journal:  Clin Biochem Rev       Date:  2010-05

3.  Two hypomorphic alleles of mouse Ass1 as a new animal model of citrullinemia type I and other hyperammonemic syndromes.

Authors:  Carlos J Perez; Jean Jaubert; Jean-Louis Guénet; Kirstin F Barnhart; Catherine M Ross-Inta; Vicente C Quintanilla; Isabelle Aubin; Jimi L Brandon; Nancy W Otto; John DiGiovanni; Irma Gimenez-Conti; Cecilia Giulivi; Donna F Kusewitt; Claudio J Conti; Fernando Benavides
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

4.  Argininosuccinate synthetase regulates hepatic AMPK linking protein catabolism and ureagenesis to hepatic lipid metabolism.

Authors:  Anila K Madiraju; Tiago Alves; Xiaojian Zhao; Gary W Cline; Dongyan Zhang; Sanjay Bhanot; Varman T Samuel; Richard G Kibbey; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

5.  The national Austrian newborn screening program - eight years experience with mass spectrometry. past, present, and future goals.

Authors:  David C Kasper; Rene Ratschmann; Thomas F Metz; Thomas P Mechtler; Dorothea Möslinger; Vassiliki Konstantopoulou; Chike B Item; Arnold Pollak; Kurt R Herkner
Journal:  Wien Klin Wochenschr       Date:  2010-10-15       Impact factor: 1.704

Review 6.  Hyperammonemia in Inherited Metabolic Diseases.

Authors:  Graziela Schmitt Ribas; Franciele Fátima Lopes; Marion Deon; Carmen Regla Vargas
Journal:  Cell Mol Neurobiol       Date:  2021-10-19       Impact factor: 4.231

7.  The role of molecular testing and enzyme analysis in the management of hypomorphic citrullinemia.

Authors:  David P Dimmock; Pamela Trapane; Annette Feigenbaum; Catherine E Keegan; Stephen Cederbaum; James Gibson; Michael J Gambello; Keith Vaux; Patricia Ward; Gregory M Rice; Jon A Wolff; William E O'Brien; Ping Fang
Journal:  Am J Med Genet A       Date:  2008-11-15       Impact factor: 2.802

Review 8.  Contrasting features of urea cycle disorders in human patients and knockout mouse models.

Authors:  Joshua L Deignan; Stephen D Cederbaum; Wayne W Grody
Journal:  Mol Genet Metab       Date:  2007-10-22       Impact factor: 4.797

Review 9.  Suggested guidelines for the diagnosis and management of urea cycle disorders.

Authors:  Johannes Häberle; Nathalie Boddaert; Alberto Burlina; Anupam Chakrapani; Marjorie Dixon; Martina Huemer; Daniela Karall; Diego Martinelli; Pablo Sanjurjo Crespo; René Santer; Aude Servais; Vassili Valayannopoulos; Martin Lindner; Vicente Rubio; Carlo Dionisi-Vici
Journal:  Orphanet J Rare Dis       Date:  2012-05-29       Impact factor: 4.123

10.  Leishmania donovani argininosuccinate synthase is an active enzyme associated with parasite pathogenesis.

Authors:  Ines Lakhal-Naouar; Armando Jardim; Rona Strasser; Shen Luo; Yukiko Kozakai; Hira L Nakhasi; Robert C Duncan
Journal:  PLoS Negl Trop Dis       Date:  2012-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.